SmartCardia Strengthens U.S. Board With Addition of Veteran Cardiac Device Leader Ken Nelson
SmartCardia Strengthens U.S. Board With Addition of Veteran Cardiac Device Leader Ken Nelson
LAUSANNE, Switzerland, March 19, 2024 /PRNewswire/ -- SmartCardia, which recently received FDA clearance for its 7-lead real-time ECG monitoring patch and cloud platform, announced today the addition Ken Nelson to its U.S. Board of Directors to help advise the company on commercialization and overall strategy.
瑞士洛桑，2024年3月19日 /PRNewswire/ — SmartCardia最近獲得美國食品藥品管理局批准的7種主要實時心電圖監測補丁和雲平台今天宣佈將肯·納爾遜加入美國董事會，以幫助就商業化和總體戰略向公司提供建議。
SmartCardia CEO, Srini Murali, noted "Ken has deep experience in the cardiac monitoring industry and an impressive track record. Over the course of his career, Ken built the commercial teams and successfully launched disruptive patch monitoring products for three of the leading players in cardiac digital health and remote patient monitoring: iRhythm, BioTelemetry and Bardy Diagnostics. He has worked with SmartCardia over the past year, and I am excited that he has now joined our team."
SmartCardia首席執行官斯里尼·穆拉利指出：“肯在心臟監護行業擁有豐富的經驗，往績令人印象深刻。在他的職業生涯中，Ken組建了商業團隊，併成功地爲心臟數字健康和遠程患者監測領域的三家領先公司推出了顛覆性的補丁監測產品：iRhythm、BioTelemetry和Bardy Diagnostics。在過去的一年裏，他一直在SmartCardia工作，我很高興他現在加入我們的團隊。”
This addition to the SmartCardia team comes on top of the recent news that Dr. Jag Singh, Professor of Medicine at Harvard Medical School and the former Clinical Director of the Cardiology Division and the Roman W. DeSanctis Endowed Chair in Cardiology at Mass General Hospital, has been named SmartCardia's Principal Medical Advisor.
最近有消息稱，哈佛醫學院醫學教授、前心臟病學部臨床主任、麻省總醫院羅曼·德桑克提斯心臟病學捐贈主席賈格·辛格博士被任命爲SmartCardia首席醫學顧問，他加入了SmartCardia團隊。
"SmartCardia is disrupting the cardiac Digital Health and Remote Patient Monitoring space once again, with an AI enabled, 7-Lead ECG real-time cardiac monitoring system that has been launched commercially in several countries in Europe and India and is expanding globally in 2024. I am excited to be a part of this highly innovative company," noted Ken Nelson.
“SmartCardia憑藉支持人工智能的7-Lead ECG實時心臟監測系統再次顛覆了心臟數字健康和遠程患者監護領域，該系統已在歐洲和印度的多個國家商業推出，並將於2024年向全球擴展。我很高興成爲這家高度創新的公司的一員，” 肯·納爾遜指出。
Ken comes with an impressive track record of success and is a leading global expert in the industry. He currently serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator the largest MedTech and Digital Health startup accelerator globally, as well as being on the Health Tech Innovation Business Advisory Board for the American Heart Association. In addition, he serves as Chairman of the Board for CardiaCare, and is an active board member for HeartX, HeartBeam, Happitech, and a handful of other disruptive cardiac Digital Health and MedTech startups. Prior to all of this, he held a variety of roles in Finance, Sales and Sales Leadership at Guidant and then Boston Scientific post the acquisition of Guidant in their Cardiac Rhythm Management Division.
Ken 擁有令人印象深刻的成功記錄，是該行業的全球領先專家。他目前是Medtech Advantage基金的合夥人，該基金與全球最大的醫療科技和數字健康創業加速器Medtech Innovator建立了獨家合作伙伴關係，同時也是美國心臟協會健康技術創新業務顧問委員會成員。此外，他還擔任CardiaCare的董事會主席，並且是HeartX、HeartBeam、Happitech以及其他幾家顛覆性的心臟數字健康和醫療科技初創公司的活躍董事會成員。在此之前，他在Guidant的財務、銷售和銷售領導層擔任過各種職務，之後又在波士頓科學收購了Guidant的心律管理部門。
About SmartCardia:
關於 SmartCardia：
SmartCardia is a leading provider of an integrated cloud platform and patch for cardiac and remote patient monitoring. Integrating accurate ECG and vital sign data with clinician cloud SaaS platform enables SmartCardia to provide actionable insights into patients' health. The solution provides excellent clinical, operational, and financial benefits to hospitals and patients globally.
SmartCardia是用於心臟和遠程患者監測的集成雲平台和補丁的領先提供商。將準確的心電圖和生命體徵數據與臨床醫生雲SaaS平台集成在一起，使SmartCardia能夠爲患者的健康狀況提供切實可行的見解。該解決方案爲全球醫院和患者提供了卓越的臨床、運營和財務收益。
SOURCE SmartCardia
來源 SmartCardia
譯文內容由第三人軟體翻譯。